Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA^® (valbenazine) capsules showed higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). The findings are being presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting in Nashville.